NCT06663696Recruiting
CRUZ Tunisia-Multivessel Registry
Evaluation of the Safety and Clinical Performance of the Biodegradable Polymer-Coated Sirolimus-Eluting Stent in All-Comer Patients With Multivessel Coronary Artery Disease
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 28 Oct 2024
- Start date
- 1 Nov 2024
- Primary completion date
- Nov 2027
- Lead sponsor
- Sahajanand Medical Technologies Limited
- Diseases
- Coronary artery disease
- NCT number
- NCT06663696
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Nov 2024 to the primary completion date, Nov 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients has a known hypersensitivity or contraindication to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, cobalt chromium, sirolimus or contrast media
Other
- Women with known pregnancy or who are lactating
- High probability of non-adherence to the follow-up requirements (due to social, psychological, or medical reasons)
- Currently participating in another study that has not completed the primary endpoint or that clinically interferes with the current registry requirements
Who the study is looking for
- Patient must be at least 18 years of age
- Patients with symptomatic coronary artery multivessel disease requiring the implantation of at least two Supraflex Cruz stents into the coronary vasculature during the index procedure
- The patient, or legal representative, has been informed of the nature of the registry and has consented to participate and authorised the collection and release of his/her medical information by signing a Patient Informed Consent Form
- The patient is willing and able to co-operate with study procedures and required follow up visits
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sahloul Hospital Coordinator of this site? Confirm its status | Sousse | Tunisia | Recruiting |
| Habib Thameur Hospital Coordinator of this site? Confirm its status | Tunis | Tunisia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.